Protelos (strontium ranelate), the only osteoporosis therapy to simultaneously increase bone formation and decrease bone resorption, was launched today by Servier Laboratories. The first in a new class of osteoporosis therapies called dual action bone agents (DABAs), Protelos is licenced for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fracture.
Recent Blog Post
March, 2024
Celebrating International Women's Day: Stories from Twins and TwinsUK Staff
25th March 2024 – by Aaruthy Suthahar International Women’s Day (IWD) on March 8th is a day to celebrate the...
March, 2024
TwinsUK part of team awarded £20 million to study bowel cancer
7th March 2024 – by TwinsUK and King’s College London TwinsUK will receive part of £20m in funding by Cancer...
February, 2024
Daily fibre supplement improves older adults’ brain function in just 12 weeks
29th February 2024 – By Aaruthy Suthahar Researcher’s from TwinsUK conducted a study on twins aged 60 and above has...